Enanta Pharmaceuticals Ownership | Who Owns Enanta Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Enanta Pharmaceuticals Ownership Summary


Enanta Pharmaceuticals is owned by 128.91% institutional investors, 4.67% insiders. Janus henderson group is the largest institutional shareholder, holding 17.70% of ENTA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.02% of its assets in Enanta Pharmaceuticals shares.

ENTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnanta Pharmaceuticals128.91%4.67%-33.58%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Janus henderson group3.78M17.70%$47.72M
Blackrock funding, inc. /de3.24M15.18%$47.30M
Krensavage asset management2.87M13.41%$41.79M
Farallon capital management2.42M11.31%$35.26M
Vanguard group2.30M10.77%$36.30M
Blackrock1.85M8.72%$23.96M
Deep track capital, lp1.44M6.75%$21.06M
Adar1 capital management1.34M6.29%$19.60M
Vanguard capital management1.21M5.67%$17.67M
Acadian asset management1.08M5.04%$15.71M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management2.87M15.88%$41.79M
Adar1 capital management1.34M0.90%$19.60M
Commodore capital lp800.00K0.47%$9.58M
Deep track capital, lp1.44M0.31%$21.06M
Pharvision advisers35.85K0.24%$429.08K
Stempoint capital lp75.19K0.18%$900.07K
Opaleye management125.00K0.17%$1.82M
Farallon capital management2.42M0.16%$35.26M
Hillsdale investment management468.00K0.16%$6.82M
Summittx capital257.70K0.10%$3.76M

Top Buyers

HolderShares% AssetsChange
Adar1 capital management1.34M0.90%1.29M
Commodore capital lp800.00K0.47%800.00K
Vanguard group2.30M0.00%362.96K
Sixth street partners management company301.15K0.00%301.15K
Summittx capital257.70K0.10%257.70K

Top Sellers

HolderShares% AssetsChange
Ra capital management---1.04M
Armistice capital---1.00M
Soleus capital management---785.55K
Deep track capital, lp1.44M0.31%-512.70K
Farallon capital management2.42M0.16%-453.66K

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp800.00K0.47%800.00K$9.58M
Sixth street partners management company301.15K0.00%301.15K$4.39M
Summittx capital257.70K0.10%257.70K$3.76M
Stempoint capital lp75.19K0.18%75.19K$900.07K
Mackenzie financial67.37K0.00%67.37K$982.21K

Sold Out

HolderChange
Sjs investment consulting-1.00
Wealth preservation advisors-2.00
Nelson, van denburg & campbell wealth management group-4.00
Advisory services network-4.00
Twin peaks wealth advisors-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026125-7.41%27,561,4662.95%1280.82%61-15.28%3712.12%
Mar 31, 2026129-1.53%26,744,9721.35%1251.48%70-14.63%3223.08%
Dec 31, 202553-57.94%8,402,898-55.75%390.50%30-50.82%11-72.50%
Sep 30, 202547-53.00%5,407,827-68.64%250.39%20-55.56%17-55.26%
Jun 30, 2025104-5.45%18,326,590-1.61%851.12%47-16.07%4110.81%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv877.12K3.02%15.99K
Vanguard Morn Total Stk Mkt Idx Investor877.12K3.02%15.99K
Vanguard MStar Total Stk Mkt Idx Invest877.12K3.01%-
Vanguard US Total Market Shares ETF629.60K2.95%-
iShares Russell 2000 ETF719.93K2.48%-12.77K
BlackRock Health Sciences Opps Inv A492.00K1.69%-
Columbia Small Cap Value I A271.73K1.28%3.30K
Hillsdale US Small Cap Eq Fund Srs A U$352.70K1.22%352.70K
Vanguard Institutional Extnd Mkt Idx Tr308.99K1.06%864.00
Vanguard Strategic Small-Cap Equity Inv280.93K0.97%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 05, 2025Capps Kathleen S. See RemarksSell$4.60K
Dec 05, 2025Trout Harry R. III See RemarksSell$7.71K
Dec 05, 2025Rottinghaus Scott T. Chief Medical OfficerSell$11.36K
Dec 05, 2025Luu Brendan Chief Business OfficerSell$19.84K
Dec 05, 2025Kieffer Tara Lynn Chief Product Strategy OfficerSell$29.97K

Insider Transactions Trends


DateBuySell
2026 Q3--
2026 Q1--
2025 Q4-9
2025 Q3--
2025 Q11-

ENTA Ownership FAQ


Who Owns Enanta Pharmaceuticals?

Enanta Pharmaceuticals shareholders are primarily institutional investors at 128.91%, followed by 4.67% insiders and -33.58% retail investors. The average institutional ownership in Enanta Pharmaceuticals's industry, Biotech Stocks , is 379.61%, which Enanta Pharmaceuticals falls below.

Who owns the most shares of Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s largest shareholders are Janus henderson group (3.78M shares, 17.70%), Blackrock funding, inc. /de (3.24M shares, 15.18%), and Krensavage asset management (2.87M shares, 13.41%). Together, they hold 46.28% of Enanta Pharmaceuticals’s total shares outstanding.

Does Blackrock own Enanta Pharmaceuticals?

Yes, BlackRock owns 8.72% of Enanta Pharmaceuticals, totaling 1.85M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 23.96M$. In the last quarter, BlackRock increased its holdings by 8.46K shares, a 0.46% change.

Who is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 15.88% of its assets in 2.87M Enanta Pharmaceuticals shares, valued at 41.79M$.

Who is the top mutual fund holder of Enanta Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Enanta Pharmaceuticals shares, with 3.02% of its total shares outstanding invested in 877.12K Enanta Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools